{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:14:13Z","timestamp":1794111253409,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-16-00013163"],"award-info":[{"award-number":["G-16-00013163"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-159928"],"award-info":[{"award-number":["FDN-159928"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106832","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:38:11Z","timestamp":1783924691000},"page":"106832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro comparison of the effects of abelacimab, dalteparin, and apixaban on catheter-induced clotting and thrombin generation"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-9964","authenticated-orcid":false,"given":"Ruiqi","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0918-5537","authenticated-orcid":false,"given":"Xinyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-0754","authenticated-orcid":false,"given":"James C.","family":"Fredenburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106832_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2026.106832_bib2","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106832_bib3","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jtha.2025.06.028","article-title":"Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation","volume":"23","author":"Yin","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106832_bib4","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1182\/bloodadvances.2022009236","article-title":"Histidine-rich glycoprotein attenuates catheter thrombosis","volume":"7","author":"Malik","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106832_bib5","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106832_bib6","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.actbio.2012.07.019","article-title":"Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo","volume":"8","author":"Yau","year":"2012","journal-title":"Acta Biomater"},{"key":"10.1016\/j.rpth.2026.106832_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtha.2022.10.020","article-title":"Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro","volume":"21","author":"Guan","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106832_bib8","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106832_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/asheducation-2014.1.306","article-title":"Central venous catheter-related thrombosis","volume":"2014","author":"Geerts","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.106832_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.actbio.2019.06.021","article-title":"The blood compatibility challenge. Part 1: Blood-contacting medical devices: the scope of the problem","volume":"94","author":"Jaffer","year":"2019","journal-title":"Acta Biomater"},{"key":"10.1016\/j.rpth.2026.106832_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.01.017","article-title":"Central venous catheter-related thrombosis in children and adults","volume":"187","author":"Citla Sridhar","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106832_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.07.002","article-title":"Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults","volume":"157","author":"Baumann Kreuziger","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106832_bib13","doi-asserted-by":"crossref","first-page":"901.e1","DOI":"10.1016\/j.amjmed.2007.05.010","article-title":"Prevention of central venous catheter-associated thrombosis: a meta-analysis","volume":"120","author":"Kirkpatrick","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2026.106832_bib14","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/jth.15487","article-title":"Venous thromboembolism associated with central venous catheters in patients with cancer: from pathophysiology to thromboprophylaxis, areas for future studies","volume":"19","author":"Debourdeau","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106832_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2026.106832_bib16","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood-2014-11-611319","article-title":"Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein","volume":"125","author":"Vu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106832_bib17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.thromres.2012.09.010","article-title":"Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study","volume":"130","author":"Elit","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106832_bib18","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.jtha.2025.06.016","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study","volume":"23","author":"Hardy","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106832_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor Xia","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106832_bib20","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2026.106832_bib21","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.108.789479","volume":"118","author":"Mehta","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2026.106832_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits","volume":"112","author":"Yau","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106832_bib23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106832_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.rpth.2026.106832_bib25","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0140-6736(25)02097-5","article-title":"Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism phase 2 trials","volume":"406","author":"Weitz","year":"2025","journal-title":"Lancet"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:56:35Z","timestamp":1790164595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926034904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926034904"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106832","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro comparison of the effects of abelacimab, dalteparin, and apixaban on catheter-induced clotting and thrombin generation","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106832"}}